Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury (Q37899155)

25 August 2017

1 reference

title

Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury (English)

1 reference

25 August 2017

2

Salvatore Cuzzocrea

1 reference

25 August 2017

Emanuela Esposito

1

1 reference

PubMed ID

21740108

25 August 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

Expert Opinion on Therapeutic Targets

25 August 2017

1 reference

25 August 2017

15

1 reference

25 August 2017

8

1 reference

25 August 2017

943-959

1 reference

Emerging repair, regeneration, and translational research advances for spinal cord injury

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Spinal glucocorticoid receptors contribute to the development of morphine tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Strategies of medical intervention in the management of acute spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptors and acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARdelta regulates glucose metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Alterations in immune cell phenotype and function after experimental spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Reducing inflammation decreases secondary degeneration and functional deficit after spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Characterization of the early neuroinflammation after spinal cord injury in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Factors associated with improved neurologic outcomes in patients with incomplete tetraplegia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Neuroprotection and acute spinal cord injury: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The role of the complement system in CNS inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Cellular and paracellular transplants for spinal cord injury: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Stimulation of neurite outgrowth using positively charged hydrogels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Neural precursor cell lines promote neurite branching

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Olfactory ensheathing cells exert a trophic effect on the hypothalamic neurons in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21.1-p21.2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Combinatorial control of gene expression by nuclear receptors and coregulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Nuclear receptors versus inflammation: mechanisms of transrepression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

A transcriptional co-repressor that interacts with nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

15-deoxy-delta12,14-prostaglandin J2 regulates the functional state and the survival of microglial cells through multiple molecular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARs and the complex journey to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

15d-PGJ2: the anti-inflammatory prostaglandin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

15-Deoxy-delta(12,14)-prostaglandin J(2) inhibits IL-1beta-induced IKK enzymatic activity and IkappaBalpha degradation in rat chondrocytes through a PPARgamma-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptor translational research and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Genetic basis of lipodystrophies and management of metabolic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Activation of PPARdelta alters lipid metabolism in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

IL-13 induces expression of CD36 in human monocytes through PPARgamma activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARs in diseases: control mechanisms of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARgamma as a therapeutic target in central nervous system diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

A Nuclear Receptor Atlas: macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARdelta/beta: the lobbyist switching macrophage allegiance in favor of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARgamma in immunity and inflammation: cell types and diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

A review of the functional role and of the expression profile of retinoid signaling and of nuclear receptors in human spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPARγ agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Potential Therapeutic Targets for PPARgamma after Spinal Cord Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

RAR/RXR and PPAR/RXR Signaling in Spinal Cord Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Chronic expression of PPAR-delta by oligodendrocyte lineage cells in the injured rat spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Inflammation: beneficial or detrimental after spinal cord injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Anti-TNF therapy in the injured spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Spinal cord injury: emerging beneficial role of reactive astrocytes' migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

Unlike PPARγ, PPARα or PPARβ/δ activation does not promote human monocyte differentiation toward alternative macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.581231

10.1517/14728222.2011.581231

21 January 2018

Identifiers

DOI

1 reference

release_bxfqjgnczbcfflpqaisrsqnkia

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bxfqjgnczbcfflpqaisrsqnkia

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

21740108

1 reference

PubMed ID

21740108